P3 trial saving #COVID19-induced #ARDS patients. Extraordinary survival outcomes seen in pilot study (83% survival in ventilator-dependent patients w/ moderate/severe ARDS): https://buff.ly/2Ky4f3s More very soon.
This surely speaks to the inner confidence Mesoblast has and the effectiveness of the trial.Trial update must be imminent.
David Oxley@CellularMedici2·Jul 12P3 trial saving...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.000(0.00%) |
Mkt cap ! $1.267B | |||
| Open | High | Low | Value | Volume |
| $1.13 | $1.13 | $1.06 | $12.24M | 11.22M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 32118 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 21178 | 2 |
View Market Depth
| Last trade - 16.10pm 31/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.10 |
Change
0.000 ( 2.07 %) |
||||
| Open | High | Low | Volume | ||
| $1.12 | $1.12 | $1.06 | 1826006 | ||
| Last updated 15.59pm 31/05/2024 ? | |||||
| MSB (ASX) Chart |